Skip to main content
About us
Who We Are
Leadership Team
Board of Directors
Advisors
AI platform technologies
Pipeline
Overview
Investors
Overview
Evaxion Shares
Share Data
Share Charts
Historical Lookup
Investment Calculator
Analyst Coverage
Reports & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Financial Calendar
Presentations
Corporate Governance
Governance Documents
Committees
Annual Shareholder Meeting
Resources
Investor FAQs
News & Events
Press Releases
Events
Stay in Touch
Careers
Contact
Contact us
Site Search
open mobile navigation
Press Releases
close mobile navigation
About us
Who We Are
Leadership Team
Board of Directors
Advisors
AI platform technologies
Pipeline
Overview
Investors
Overview
Evaxion Shares
Share Data
Share Charts
Historical Lookup
Investment Calculator
Analyst Coverage
Reports & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Financial Calendar
Presentations
Corporate Governance
Governance Documents
Committees
Annual Shareholder Meeting
Resources
Investor FAQs
News & Events
Press Releases
Events
Stay in Touch
Careers
Contact
Contact us
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
06/30/2022
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
06/23/2022
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
06/07/2022
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
05/11/2022
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
05/10/2022
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02
04/29/2022
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11
04/06/2022
Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies
03/22/2022
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
03/14/2022
Evaxion Biotech Strengthens Management Team with Two Senior Appointments
03/07/2022
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
01/26/2022
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
01/18/2022
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma